DrugDashboards

Clindamycin

Clindamycin Phosphate · CLINDAMYCIN PHOSPHATE 150 mg/mL · Injection, Solution · Intramuscular; Intravenous · Sagent Pharmaceuticals

NDC 25021-0115-02 · 25 VIAL in 1 CARTON / 2 mL in 1 VIAL · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$1.97per billing unit (300 MG)HCPCS J0736 · Jul 1, 2026
  • Part D plans paid (avg)$57.82per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$1.27per unitnegotiated price across 5,326 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$1.27per unit
middle half $0.8926–$1.55 · 5,326 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $1.27
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
97%of plans cover it
tier 4 · prior auth 7% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$85.35
Reported to Texas DSHS · 2026 annual filing · Sagent Pharmaceuticals

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 300 MG
$1.974
HCPCS J0736 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$1,344
170 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 4 across plans
  • Costs ≥ $950/fill · avg $38.65 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA090108
TE code
AP
Approval date
Sep 30, 2011
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)Jun 1, 2026
  • In shortage now — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)Mar 21, 2023
    Demand increase for the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)Mar 21, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)Mar 21, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Clindamycin Phosphate (Injection, Solution)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 300 mg/50mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 900 mg/50mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 600 mg/50mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 3, 2026
Pharmacia & Upjohn Company LLCCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CorporationCLINDAMYCIN PHOSPHATE 600 mg/50mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationCLINDAMYCIN PHOSPHATE 900 mg/50mLJul 15, 2026Sep 2, 2026
ProPharma DistributionCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.CLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clindamycin — NDC 25021-0115-02," retrieved September 3, 2026, https://drugdashboards.com/drug/25021011502.

Free to cite with attribution — see how the data is put together.